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patients with multiple myeloma (MM). Combining standard frac-
tionated total body irradiation (TBI) with high-dose melphalan
precludes optimal dosing of melphalan, and results in equivalent
efﬁcacy but more toxicity in comparison to high-dose melphalan
(mel) alone. Helical tomotherapy is a novel tool for delivering CT
image guided intensity modulated radiation therapy and may allow
for greater doses of total marrow irradiation (TMI) and less col-
lateral damage to other organs. We set out to test the feasibility of
THDT inclusive of TMI. Eligible patients (70 years old, with
stages I-III MM, in response or with stable disease, with a creati-
nine clearance of 50 mL/min) underwent mobilization with cy-
clophosphamide 1.5 gm/m2 and G-CSF 10 microgram/kg and
procurement of  4  106 CD34 cells/kg. THDCT consisted
of a set dose of mel 200 mg/m2 followed by PBPC. At a
minimum of 6 weeks later, TMI 200 cGy daily  5 days, (to be
escalated up to 200 cGy twice daily in a standard phase one
cohort by cohort fashion) an PBPC is administered. Upon
recovery, thalidomide 50–200 mg daily and dexamethasone 40
mg/day  4 days every 28 days is to be prescribed. At dose level
1 (TMI: 200 cGy daily  5 days ) two patients (a 53 year old
female with stage I MM in complete response and a 48 year old
male with stage III MM in partial response prior to THDT)
have completed THDT and are currently receiving mainte-
nance. Neutrophyl and platelet recovery following TMI was
observed by days 9 and 11, and platelet independence (deﬁned as
the day after the last platelet transfusion) was observed by day
10. Grade 1 emesis and grade 2 nausea, but no evidence of oral
mucositis, enteritis, or skin erythema were noted. The estimated
reduction in organ exposure to radiation with TBI versus TMI
ranged from 6.5–6.9-fold (lens) to 2.5–2.6-fold (bowel), and
1.4–1.7-fold (lungs) in the ﬁrst two patients treated. TMI is
feasible for patients undergoing THDT for MM. Accrual is
ongoing and results in patients treated at higher doses of TMI
will be presented.
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Introduction: Low risk, curative therapy for patients with
multiple myeloma remains elusive. Autologous stem cell trans-
plant remains the standard of care for newly diagnosed multiple
myeloma. Mobilization of adequate CD34 cells can be a dif-
ﬁcult task, especially in patients who have been heavily pre-
treated. We have compared the three mobilization regimens
utilized at our facility and the subsequent CD34 collections.
Background: Standard chemotherapy is effective in maintain-
ing control of multiple myeloma, however none has proven
curative. Several trials have indicated that tandem or double
autologous transplants may provide a signiﬁcant beneﬁt for
overall survival and event free survival. When double trans-
plants are planned, especially for patients who are heavily pre-
treated, collection of adequate CD34 cells can prove to be
challenging. Methods: 217 patients with multiple myeloma
whose treatment plan included either a single or double autol-
ogous transplant were evaluated retrospectively. Data have been
collected from January 1999 to March 2005. Mobilization reg-
imens utilized were etoposide/cyclophosphamideGCSF,
60 patients; cyclophosphamideGCSF, 34 patients; and
GCSF alone, 123 patients. Peripheral blood stem cells were
collected following standard institutional procedures utilizing
the Cobe Spectra apheresis machine. Standard CD34 cell dose
target for a single transplant was 	2.0  106/kg. Results:
Average and median CD34 cell dose collected for patients
receiving GCSF alone was 24.05  106/kg and 6.3  106/kg;
cyclophosphamideGCSF 13.28  106/kg and 9.75  106/kg;
etoposide/cyclophosphamideGCSF 39.98  106/kg and
30.4  106/kg. The average number of collections required
for each regimen was 2.11 days for GCSF, 1.76 days for
cyclophosphamideGCSF, and 1.4 days for etoposide/cyclophosph-
amideGCSF.Conclusions: Etoposide/cyclophosphamideGCSF
mobilization regimen is highly effective in mobilizing large numbers
of CD34 cells in multiple myeloma patients making double or
tandem transplants a viable treatment option.
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Background: Salvage chemotherapy is used for cytoreduction
and PBSC mobilization in patients with relapsed and refractory
lymphomas. Hospitalization is generally required for administra-
tion of the most commonly used regimens. We conducted a pilot
study to determine the feasibility of delivering CCE with or with-
out rituximab for cytoreduction and chemomobilization entirely in
the outpatient setting to patients with refractory or recurrent
non-Hodgkin’s or Hodgkin’s lymphoma who were candidates for
high dose therapy with autologous stem cell support. Methods: 2
cycles of CCE were administered at 21 day intervals. The regimen
consisted of cyclophosphamide 1 gram/m2 on day 1, carboplatin at
an AUC of 5 on day 2, and etoposide 100 mg/m2 on days 1, 2, and
3. G-CSF, 5 mcg/kg/day was administered on days 512 with
cycle 1 and the dose was increased to 10 mcg/kg/day for PBSC
mobilization with cycle 2. After the ﬁrst 8 patients, the protocol
was amended to allow the use of rituximab at a dose of 375
mg/m2on days 1, 8, and 15 of each cycle for those patients with
CD20 lymphomas. Results: 18 patients have been enrolled and
have completed CCE. The diagnoses include B-cell non-
Hodgkin’s lymphoma (B-NHL; n  8 large cell, n  2 follicular),
Hodgkin’s lymphoma (n  3), peripheral T-cell lymphoma (n 
2), anaplastic large cell lymphoma (n  1), composite B-NHL/
Hodgkin’s lymphoma (n  1), and T-cell rich, B-cell lymphoma
(n  1). The median age was 46 years (range 19–69). One patient
received one cycle of CCE, while 2 patients received more than 2
cycles. The overall response rate for the regimen is 63% (3 CR, 7
PR, 5 SD, 1 PD, 2 not evaluable). PBSC were collected successfully
from 16/18 patients. The median number of PBSC collected was
7.5  106 CD34 cells/kg (range 2.1–16.8  106), and the median
number of apheresis sessions was 2 (range 1–9). There were 4
hospitalizations for neutropenic fever in 38 cycles. Non-hemato-
logic toxicity was minimal, and no deaths occurred on study. All
patients from whom sufﬁcient PBSC were collected underwent
high dose therapy with autologous PBSC rescue, and hematologic
recovery occurred in 100%. Conclusions: The interim results of
this pilot study suggest that CCE is a safe and effective outpatient
regimen for cytoreduction and PBSC mobilization for relapsed or
refractory non-Hodgkin’s and Hodgkin’s lymphoma. This regi-
men warrants further study, and a total of 30 patients will be
enrolled on this continuing study.
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Introduction: Most patients undergoing high-dose therapy and
autologous transplant for multiple myeloma eventually relapse.
The optimal treatment for these patients is still evolving. There
have been few reports of autologous transplants in the salvage
setting. We analyzed the outcome of salvage autologous transplant
in 22 patients with disease progression after the ﬁrst autograft.
Methods: These patients in general were not eligible for an allo-
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